AUPM456894A0 - Treatment for gastric disorders - Google Patents

Treatment for gastric disorders

Info

Publication number
AUPM456894A0
AUPM456894A0 AUPM4568A AUPM456894A AUPM456894A0 AU PM456894 A0 AUPM456894 A0 AU PM456894A0 AU PM4568 A AUPM4568 A AU PM4568A AU PM456894 A AUPM456894 A AU PM456894A AU PM456894 A0 AUPM456894 A0 AU PM456894A0
Authority
AU
Australia
Prior art keywords
treatment
gastric disorders
gastric
disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AUPM4568A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glyzinic Pharmaceuticals Ltd
Original Assignee
Glyzinic Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glyzinic Pharmaceuticals Ltd filed Critical Glyzinic Pharmaceuticals Ltd
Priority to AUPM4568A priority Critical patent/AUPM456894A0/en
Publication of AUPM456894A0 publication Critical patent/AUPM456894A0/en
Priority to PCT/AU1995/000146 priority patent/WO1995025513A1/en
Priority to AU20611/95A priority patent/AU2061195A/en
Abandoned legal-status Critical Current

Links

Classifications

    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/28Compounds containing heavy metals
    • A61K31/315Zinc compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/555Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/30Zinc; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Nanotechnology (AREA)
  • Inorganic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AUPM4568A 1994-03-18 1994-03-18 Treatment for gastric disorders Abandoned AUPM456894A0 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AUPM4568A AUPM456894A0 (en) 1994-03-18 1994-03-18 Treatment for gastric disorders
PCT/AU1995/000146 WO1995025513A1 (en) 1994-03-18 1995-03-17 Zinc compound and cyclodextrine for treatment of gastric disorders
AU20611/95A AU2061195A (en) 1994-03-18 1995-03-17 Zinc compound and cyclodextrine for treatment of gastric disorders

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AUPM4568A AUPM456894A0 (en) 1994-03-18 1994-03-18 Treatment for gastric disorders

Publications (1)

Publication Number Publication Date
AUPM456894A0 true AUPM456894A0 (en) 1994-04-14

Family

ID=3779183

Family Applications (1)

Application Number Title Priority Date Filing Date
AUPM4568A Abandoned AUPM456894A0 (en) 1994-03-18 1994-03-18 Treatment for gastric disorders

Country Status (2)

Country Link
AU (1) AUPM456894A0 (en)
WO (1) WO1995025513A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69637442T2 (en) * 1995-12-22 2008-05-21 Nagase Chemtex Corp. ACTIVE AGAINST HELICOBACTER PYLORI
GB9621273D0 (en) 1996-10-11 1996-11-27 Cortecs Ltd Therapeutic method
EP1735326A4 (en) * 2004-01-29 2011-04-20 Pinnacle Pharmaceuticals Beta-cyclodextrin derivatives and their use against anthrax lethal toxin
MX2007000201A (en) 2004-06-30 2007-06-15 Nutrition Sciences Nv Medium chain fatty acids applicable as anti-microbial agents.
DK1976532T3 (en) 2006-01-27 2016-02-01 Univ Yale FAST-ACTING INHIBITOR of gastric acid secretion
US8512761B2 (en) 2006-01-27 2013-08-20 Yale University Fast acting inhibitor of gastric acid secretion
US9420795B2 (en) 2011-07-27 2016-08-23 Matterworks One Limited Glycolate formulation for preserving wood and like materials
CN106511351B (en) * 2016-12-27 2020-04-03 吉林省博大伟业制药有限公司 Application of polaprezinc in preparation of anti-helicobacter pylori medicines
IT202000025066A1 (en) * 2020-10-22 2022-04-22 Difass Int S R L COMPOSITION INCLUDING MACROCYSTIS PYRIFERA, CARNOSINE AND ZINC FOR THE TREATMENT OF HELICOBACTER PYLORI INFECTION

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5095035A (en) * 1981-07-31 1992-03-10 Eby Iii George A Flavor stable zinc acetate compositions for oral absorption
JPH072629B2 (en) * 1987-07-01 1995-01-18 花王株式会社 Water-soluble antibacterial agent and cosmetics containing the same
GB9004328D0 (en) * 1990-02-27 1990-04-25 Glaxo Group Ltd Chemical compounds
JPH06172189A (en) * 1992-08-17 1994-06-21 Bristol Myers Squibb Co Composite agent for protection of stomach and intestine
IT1263831B (en) * 1993-01-29 1996-09-04 Paolo Chiesi MULTI-COMPONENT INCLUSION COMPLEXES WITH HIGH SOLUBILITY CONSTITUTED BY A BASIC-TYPE DRUG, AN ACID AND A CYCLODEXTRINE

Also Published As

Publication number Publication date
WO1995025513A1 (en) 1995-09-28

Similar Documents

Publication Publication Date Title
AUPM864894A0 (en) Treatment of bowel-dependent neurological disorders
AU3153295A (en) Methods for treating addictive disorders
AU2805195A (en) Therapeutic compounds
AU1139095A (en) Combination treatment for osteoporosis
AU3341395A (en) Vibration-compensating apparatus
AU7772794A (en) Treatment of obesity
AU2474195A (en) Catheter apparatus
AU1542895A (en) Surface treatment
AU3095595A (en) Dimension-measuring apparatus
AU2424895A (en) Substituted spirodienes for the treatment of inflammation
AU2555397A (en) Macrophage stimulating protein for the treatment of gastrointestinal disorders
AU2557895A (en) Composition for treating gastrointestinal disorders
AUPM456894A0 (en) Treatment for gastric disorders
AU8179494A (en) Tab for can
AU6927894A (en) 4-amidinophenylsulphonamides for the treatment of thrombo-embolitic conditions
AU2705195A (en) Incontinence treatment
AU2547895A (en) Therapeutic phenoxyalkylheterocycles
AU7018794A (en) Methods for treating pathologies
AU3860995A (en) Adjusting means
AU6581294A (en) Ethanolamine derivatives useful for the treatment of gastrointestinal disorders
EP0724842A3 (en) Preparation for the treatment of obesity
AU2291595A (en) Turning apparatus
AU3874795A (en) Oral treatment
AU2671895A (en) Bisquinolines for the treatment of malaria
AU2245695A (en) Composition for treating neurological disorders